$NYMX breakout $3.97 Nasdaq CM Website htt
Post# of 63818
Posted On: 07/23/2016 1:50:42 PM
$NYMX breakout $3.97
Nasdaq CM
Website
Shares Outstanding 43.81M
Float 26.09M
% Held by Insiders 6.10%
% Held by Institutions 1 2.80%
Shares Short 31.85M
Short Ratio 4.17
Short % of Float 37.15%
Shares Short (prior month) 31.56M
Headlines
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population. It markets NicAlert and TobacAlert test strips that use urine or saliva to detect use of tobacco products. The company also offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimers disease. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which is in Phase III clinical trials for the treatment of enlarged prostate or benign prostatic hyperplasia, as well as is in Phase II clinical trial for low grade localized prostate cancer. The company markets its products in Canada, the United States, Europe, and internationally. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Nassau, The Bahamas.
Nasdaq CM
Website
Shares Outstanding 43.81M
Float 26.09M
% Held by Insiders 6.10%
% Held by Institutions 1 2.80%
Shares Short 31.85M
Short Ratio 4.17
Short % of Float 37.15%
Shares Short (prior month) 31.56M
Headlines
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population. It markets NicAlert and TobacAlert test strips that use urine or saliva to detect use of tobacco products. The company also offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimers disease. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which is in Phase III clinical trials for the treatment of enlarged prostate or benign prostatic hyperplasia, as well as is in Phase II clinical trial for low grade localized prostate cancer. The company markets its products in Canada, the United States, Europe, and internationally. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Nassau, The Bahamas.
(0)
(0)